key: cord-0827226-wtpq9qgq
authors: Assini, Andrea; Gandoglia, Ilaria; Damato, Valentina; Rikani, Klaudio; Evoli, Amelia; Del Sette, Massimo
title: Myasthenia gravis associated with anti‐MuSK antibodies developed after SARS‐CoV‐2 infection
date: 2021-01-09
journal: Eur J Neurol
DOI: 10.1111/ene.14721
sha: c70ebef115c9e2cc5c9b1caee940ad9b092a09bf
doc_id: 827226
cord_uid: wtpq9qgq

INTRODUCTION: Since the onset of the novel coronavirus pandemic, several neurological complications secondary to SARS‐CoV‐2 infection have been reported, affecting central nervous system, peripheral nervous system and neuromuscular junction. CASE REPORT: We present the case of a 77‐year‐old man who developed bulbar myasthenia gravis (MG) eight weeks after SARS‐CoV‐2 infection. The search for serum antibodies against the acetylcholine receptor, the muscle‐specific tyrosine kinase (MuSK), and the low‐density lipoprotein receptor‐related protein 4 antibodies, performed by radioimmunoassay (RIA), resulted negative, while anti‐MuSK antibodies were detected by cell‐based assay (CBA). The patient was treated with pyridostigmine (60 mg four times a day) with unsatisfactory clinical response, followed by immunosuppressive therapy (azathioprine 1.5 mg/kg/day) with improvement of MG symptoms after two months of treatment. DISCUSSION: Several viral diseases have been described as associated with the onset of MG, although the underlying mechanisms are not yet fully understood. Similarly, a growing number of scientific reports suggest a correlation between SARS‐CoV‐2 infection and autoimmune diseases. The interest of our case lies in the timing of the MG onset (after two months from infection), together with the unusual late onset of anti‐MuSK MG. These elements suggest that coronavirus infection may act as a trigger of the disease. We confirm the importance of CBA in the serological diagnosis of RIA‐negative MG.

Since the onset of the novel coronavirus pandemic, several neurological complications secondary to SARS-CoV-2 infection have been reported, affecting central nervous system, peripheral nervous system and neuromuscular junction.

We present the case of a 77-year-old man who developed bulbar myasthenia gravis (MG) eight weeks after SARS-CoV-2 infection. The search for serum antibodies against the acetylcholine receptor, the muscle-specific tyrosine kinase (MuSK), and the low-density lipoprotein receptorrelated protein 4 antibodies, performed by radioimmunoassay (RIA), resulted negative, while anti-MuSK antibodies were detected by cell-based assay (CBA). The patient was treated with pyridostigmine (60 mg four times a day) with unsatisfactory clinical response, followed by immunosuppressive therapy (azathioprine 1.5 mg/kg/day) with improvement of MG symptoms after two months of treatment.

Several viral diseases have been described as associated with the onset of MG, although the un- 

We describe the case of a 77-year-old man without relevant past medical history, who was diagnosed with SARS-CoV-2 infection in March 2020. He presented with bilateral interstitial pneumonia, dyspnea and fever. His clinical conditions slowly improved and the oropharyngeal swab turned negative after 42 days from diagnosis. Eight weeks after the onset of SARS-CoV-2 infection, the patient complained of chewing difficulty, dysphonia, diplopia, and eyelid ptosis, worsened by muscular activity, suggestive for MG. No weakness of limbs or respiratory muscles was evident. The diagnosis of MG was confirmed by the electrophysiological study (repetitive nerve stimulation and single fiber electromyography). Chest CT scan was negative for thymic changes.

Radioimmunoassay (RIA) for anti-AChR, and anti-MuSK antibodies was performed twice (at disease onset and after one month) and resulted negative, as well as the low-density lipoprotein receptor-related protein 4 (LRP4) antibodies tested by immunohistochemistry. Therefore, patient serum was tested by cell-based assay (CBA) 5 around 3 months after disease onset, and resulted positive for anti-MuSK antibodies (Fig. 1) . As the response to pyridostigmine (60 mg four times a day) was unsatisfactory, immunosuppressive therapy with azathioprine was started, reaching 

This article is protected by copyright. All rights reserved 85% of MG patients have anti-AChR antibodies and around 40% of AChR antibody-negative have anti-MuSK antibodies 7 . More recently, antibodies directed against other proteins of the NMJ, as LRP4 antibodies, have been described in a low proportion of patients 7 . The use of the CBA technique, which has a higher sensitivity than RIA but retains the same specificity, has proven helpful in the serological diagnosis of RIA negative MG cases 7 . This patient was affected by mild MG symptoms that were easily managed with low-dose immunosuppression. This finding is in agreement with earlier observations that patients positive only on CBA have milder MG than RIA-positive cases 5 .

It has long been known that infections can both precede the onset of MG and trigger disease deteriorations, as with other autoimmune disorders 8 

Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient

Myasthenia Gravis Associated With SARS-CoV-2 Infection

New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review

COVID-19 in muscle-specific kinase myasthenia gravis: A case report. Muscle Nerve [online serial

IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG

Myasthenia gravis with antibodies to MuSK: an update

Myasthenia gravis

Myasthenia gravis and infectious disease

Neurological associations of COVID-19

All the plasmids used in this study were kind gifts from Professor Angela Vincent and Professor David Beeson, Nuffield Department of Clinical Neurosciences, University of Oxford.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

This article is protected by copyright. All rights reserved